BR112022014706A2 - Moduladores da via de resposta integrada ao estresse - Google Patents

Moduladores da via de resposta integrada ao estresse

Info

Publication number
BR112022014706A2
BR112022014706A2 BR112022014706A BR112022014706A BR112022014706A2 BR 112022014706 A2 BR112022014706 A2 BR 112022014706A2 BR 112022014706 A BR112022014706 A BR 112022014706A BR 112022014706 A BR112022014706 A BR 112022014706A BR 112022014706 A2 BR112022014706 A2 BR 112022014706A2
Authority
BR
Brazil
Prior art keywords
pathway modulators
response pathway
integrated response
stress integrated
compounds
Prior art date
Application number
BR112022014706A
Other languages
English (en)
Inventor
Victoria Atton Holly
John Brown Christopher
Lindsay Carr James
Alexander Sadler Scott
Paul Shine Jonathan
Simon Walter Daryl
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of BR112022014706A2 publication Critical patent/BR112022014706A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

MODULADORES DA VIA RESPOSTA INTEGRADA AO ESTRESSE. A presente invenção refere-se a compostos de fórmula (I) ou sais, solvatos, hidratos, tautômeros ou estereoisômeros farmaceuticamente aceitáveis dos mesmos, em que R1, R2, R2a, R3, Ra1, Ra2, Ra3, Ra4, Ra5, Ra6, A1 e A2 possuem o significado conforme indicado na descrição e reivindicações. A invenção refere-se ainda a composições far-macêuticas compreendendo os referidos compostos, seu uso como medicamento e em um método para o tratamento e prevenção de uma ou mais doenças ou distúrbios associados à resposta integrada ao estresse.
BR112022014706A 2020-03-11 2021-03-10 Moduladores da via de resposta integrada ao estresse BR112022014706A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162329 2020-03-11
PCT/EP2021/056023 WO2021180774A1 (en) 2020-03-11 2021-03-10 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
BR112022014706A2 true BR112022014706A2 (pt) 2022-10-11

Family

ID=69804610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014706A BR112022014706A2 (pt) 2020-03-11 2021-03-10 Moduladores da via de resposta integrada ao estresse

Country Status (11)

Country Link
US (1) US20230129907A1 (pt)
EP (1) EP4117780A1 (pt)
JP (1) JP2023517944A (pt)
KR (1) KR20220151635A (pt)
CN (1) CN115190813A (pt)
AU (1) AU2021236284A1 (pt)
BR (1) BR112022014706A2 (pt)
CA (1) CA3165813A1 (pt)
IL (1) IL296220A (pt)
MX (1) MX2022011143A (pt)
WO (1) WO2021180774A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021363616A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
KR20230110511A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
JP2023546225A (ja) 2020-10-22 2023-11-01 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合ストレス応答経路のモジュレーター

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988301B1 (en) 1997-06-12 2006-08-09 Aventis Pharma Limited Imidazolyl-cyclic acetals
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2017212425A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
BR112020000086A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
BR112020000122A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
AU2018313850B2 (en) * 2017-08-09 2022-12-22 Denali Therapeutics Inc. Compounds, compositions and methods
SI3676297T1 (sl) * 2017-09-01 2023-12-29 Denali Therapeutics Inc. Spojine, sestavki in postopki
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
CA3080948A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090074A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
IL274406B2 (en) 2017-11-02 2024-04-01 Calico Life Sciences Llc Combined pressure pathway modulators
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
US20210205277A1 (en) 2017-11-02 2021-07-08 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3085132A1 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US20210130308A1 (en) 2018-03-23 2021-05-06 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
BR112020023115A2 (pt) 2018-06-05 2021-02-02 Praxis Biotech LLC inibidores da via integrada de resposta a tensão
JP2021529814A (ja) 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化学化合物
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
SG11202108552QA (en) 2019-02-13 2021-09-29 Denali Therapeutics Inc Compounds, compositions and methods
CA3130511A1 (en) 2019-02-25 2020-09-03 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US20220177456A1 (en) 2019-03-06 2022-06-09 Denali Therapeutics Inc. Compounds, compositions and methods
SG11202111362SA (en) 2019-04-23 2021-11-29 Evotec Int Gmbh Modulators of the integrated stress response pathway
KR20220004105A (ko) 2019-04-23 2022-01-11 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
CN114401952A (zh) 2019-04-30 2022-04-26 卡里科生命科学有限责任公司 作为整合应激通路的调节剂的被取代的环烷基化合物
CN114206848A (zh) 2019-04-30 2022-03-18 卡里科生命科学有限责任公司 作为整合应激通路的调节剂的被取代的环烷基化合物
EP3982965A4 (en) 2019-06-12 2023-01-25 Praxis Biotech LLC INTEGRATED STRESS RESPONSE PATHWAY MODULATORS
EP3983378A4 (en) 2019-06-12 2023-12-13 Praxis Biotech LLC INHIBITORS OF THE INTEGRATED STRESS RESPONSE PATHWAY

Also Published As

Publication number Publication date
WO2021180774A1 (en) 2021-09-16
JP2023517944A (ja) 2023-04-27
US20230129907A1 (en) 2023-04-27
IL296220A (en) 2022-11-01
MX2022011143A (es) 2022-10-13
EP4117780A1 (en) 2023-01-18
AU2021236284A1 (en) 2022-08-18
CA3165813A1 (en) 2021-09-16
KR20220151635A (ko) 2022-11-15
CN115190813A (zh) 2022-10-14

Similar Documents

Publication Publication Date Title
BR112021020402A2 (pt) Moduladores da via de resposta ao estresse integrada
BR112022014706A2 (pt) Moduladores da via de resposta integrada ao estresse
BR112022012643A2 (pt) Moduladores da via de resposta ao estresse integrada
BR112021020106A2 (pt) Moduladores da via de resposta ao estresse inte-grado
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015020242A2 (pt) sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
BR112014016808A2 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112014016157A2 (pt) derivados heterobicíclicos como inibidores de vhc
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112022024840A2 (pt) Combinação de alcaftadina e um corticosteroide
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
BR112022001393A2 (pt) Forma cristalina do inibidor de atr e seu uso
BR112014016007A2 (pt) derivados de quinazolinona como inibidores de vhc
BR112018073743A2 (pt) composto, processo, método para tratamento de infecção bacteriana em um sujeito, uso de um composto, e composições farmacêuticas
BR112023020538A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
BR112018070370A2 (pt) glucono delta-lactona para tratamento de infecções fúngicas vaginais
BR112014010462A2 (pt) processo para a preparação de acilguanidinas e acetioureias